Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

Michael L.  Freeman

Michael L. Freeman, Ph.D.

Professor of Radiation Oncology
VICC Member

Contact Information:

Vanderbilt Department of Radiation Oncology
Medical Center North, E-1200
Nashville, TN 37232

Research Description

The Freeman laboratory focuses on two aspects of cancer drug development: 1) Development of efficacious sensitizers of ionizing radiation . 2-Indol-3-yl-methylenequinuclidin-3-ols are being used as the basis for development of novel radiation sensitizers. Defined DNA substrates, cell and animals models are used in the approach to design specific sensitizers. 2) Providing a rationale basis for development of chemoprevention agents. Expression of the genes that encode Phase II detoxification proteins is regulated by the transcription factor Nrf2,which itself is negatively regulated by association to the Cul-3 ubiquitin ligase adaptor protein Keap1. Proteomics, biochemical, biophysical and genetic approaches are used to determine if Keap1's activity is regulated by multiple Cys residues that exhibit differential chemical reactivity, allowing integration of different chemical input signals.